These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies. Beekes M; McBride PA FEBS J; 2007 Feb; 274(3):588-605. PubMed ID: 17288548 [TBL] [Abstract][Full Text] [Related]
26. In vivo model for the evaluation of molecules active towards transmissible spongiform encephalopathies. Ponti W; Sala M; Pollera C; Braida D; Poli G; Bareggi S Vet Res Commun; 2004 Aug; 28 Suppl 1():307-10. PubMed ID: 15372984 [No Abstract] [Full Text] [Related]
28. Prion protein interconversions. Caughey B Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):197-200; discussion 200-2. PubMed ID: 11260800 [TBL] [Abstract][Full Text] [Related]
29. [Prions and their characteristics in light of recent tests]. Szostek S; Zgórniak-Nowosielska I Przegl Lek; 1999; 56(4):321-3. PubMed ID: 10494173 [TBL] [Abstract][Full Text] [Related]
30. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Gregori L; Gurgel PV; Lathrop JT; Edwardson P; Lambert BC; Carbonell RG; Burton SJ; Hammond DJ; Rohwer RG Lancet; 2006 Dec; 368(9554):2226-30. PubMed ID: 17189034 [TBL] [Abstract][Full Text] [Related]
31. Elimination of transmissible spongiform encephalopathy infectivity and decontamination of surgical instruments by using radio-frequency gas-plasma treatment. Baxter HC; Campbell GA; Whittaker AG; Jones AC; Aitken A; Simpson AH; Casey M; Bountiff L; Gibbard L; Baxter RL J Gen Virol; 2005 Aug; 86(Pt 8):2393-2399. PubMed ID: 16033987 [TBL] [Abstract][Full Text] [Related]
32. Resistance of transmissible spongiform encephalopathy agents to decontamination. Taylor DM Contrib Microbiol; 2001; 7():58-67. PubMed ID: 11923936 [No Abstract] [Full Text] [Related]
33. Transmissible spongiform encephalopathies: in-vitro evaluation of the therapeutic potentiality of new molecules. Carcassola G; Giannino ML; Riva F; Ponti W Vet Res Commun; 2003 Sep; 27 Suppl 1():331-3. PubMed ID: 14535423 [No Abstract] [Full Text] [Related]
34. Prion encephalopathies of animals and humans. Prusiner SB Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114 [TBL] [Abstract][Full Text] [Related]
35. Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy. Bartz JC; Bessen RA; McKenzie D; Marsh RF; Aiken JM J Virol; 2000 Jun; 74(12):5542-7. PubMed ID: 10823860 [TBL] [Abstract][Full Text] [Related]
36. Probing the dynamics of prion diseases with amphotericin B. Adjou KT; Deslys JP; Demaimay R; Dormont D Trends Microbiol; 1997 Jan; 5(1):27-31. PubMed ID: 9025232 [TBL] [Abstract][Full Text] [Related]
37. Critical factors influencing prion inactivation by sodium hydroxide. Bauman PA; Lawrence LA; Biesert L; Dichtelmüller H; Fabbrizzi F; Gajardo R; Gröner A; Jorquera JI; Kempf C; Kreil TR; von Hoegen I; Pifat DY; Petteway SR; Cai K Vox Sang; 2006 Jul; 91(1):34-40. PubMed ID: 16756599 [TBL] [Abstract][Full Text] [Related]